InVivoAct™

Investigate RNAi In Vivo Activity with Negative and Positive Controls

  

Use InVivoActTM to:

  • Perform in vivo RNAi studies with standardized control groups 
  • Prioritize promising gene targets relative to clinically validated targetsUse of InVivoPlex® with InVivoActTM–hVEGF, a clinically validated target for lung cancer, to treat mice bearing H460 NSCLC subcutaneous tumor 3 times per week for two weeks, results in tumor growth inhibition equivalent to that of an approved mAb therapeutic using an identical regimen with the same tumor.

 

InVivoActTM RNAi reagents provide standardized negative and positive control treatment groups for in vivo RNAi studies.  The reagents are provided in a kit designed for InVivoPlex®, or can be used with other in vivo RNAi formulations. 

Features

  •    Standardized negative and positive control RNAi agents designed for in vivo studies
  •    The negative control RNAi agent lacks biological effects on murine disease models
  •    The positive control RNAi agents have been designed for high potency, high selectivity
  •    Can be used in multiple dose regimens, dose response studies, to simulate targeted therapy

 

Points To Consider

Use InVivoActTM to evaluate gene or protein inhibition in vivo:

InVivoActTM–neg can be used to provide a negative control treatment group in studies to evaluate gene and protein inhibition by in vivo RNAi formulations, such as InVivoPlex®–Tumor.  For these studies, we recommend three doses such as on Monday, Wednesday, and Friday, with gene or protein levels assayed the following Monday, comparing the experimental RNAi group to the negative control treatment group.  

 Evaluate experimental therapeutic targets in vivo with InVivoPlex®:

 Use of in vivo RNAi formulations to evaluate candidate therapeutic targets identified with in vitro RNAi studies will usually require repeated doses to show an effect on tumor behavior, and will require multiple treatment groups with negative controls and ideally a positive control RNAi agent.  InVivoActTM kits have been developed to provide negative and positive controls, and are designed for easy use with InVivoPlex®–Tumor.  InVivoActTM–hVEGF was shown to inhibit H460 tumor as well as the approved mAb therapeutic, and can be used to facilitate validation of more potent targets in similar tumor cell pathways.  Other InVivoActTM positive control kits are available for other clinically validated targets, for studies that require a positive control in other biochemical pathways. 

 Regulatory issues for performing InVivoPlex® studies:

Use of animals for scientific research usually is subject to national and in some cases regional or local laws.  For laboratories in the US AparnaBio can help provide draft protocol language and guidance as well as links to information available from the US Government, and gladly discuss how use of InVivoActTM kits can be described to review committees, including a description of how its use is consistent with established humane use of experimental animals. 

 

Product Summary

InVivoActTM reagents enable in vivo RNAi studies, providing standardized negative and positive control treatment groups for comparison in studies with experimental RNAi agents.  With these control treatment groups, such studies can produce clinically relevant information on tumor gene function, candidate targets for therapeutic intervention, and in vivo validation of RNAi therapeutic candidates.  The InVivoActTM kits supply a concentrated solution of the standardized RNAi agent and all required buffers for in vivo studies, as well as Vehicle Control Buffer for a vehicle control treatment group.  These reagents are designed for easy use with InVivoPlex® or can be used with other in vivo RNAi formulations.  InVivoActTM Kits are available for a negative RNAi that has low activity in murine disease models, and for several clinically validated targets, including human VEGF and human EGFr.  Kits for other group sizes can be provided upon request. 

For more information, please contact us by phone or email.